Premium
Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series
Author(s) -
Brivio Erica,
Chantrain Christophe F.,
Gruber Tanja A.,
Thano Adriana,
Rialland Fanny,
Contet Audrey,
Elitzur Sarah,
DallaPozza Luciano,
Kállay Krisztián Miklós,
Li Chikong,
Kato Motohiro,
Markova Inna,
Schmiegelow Kjeld,
Bodmer Nicole,
Breese Erin H.,
Hoogendijk Raoull,
Pieters Rob,
Zwaan Christian Michel
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17333
Subject(s) - medicine , refractory (planetary science) , pediatrics , minimal residual disease , confidence interval , complete remission , surgery , chemotherapy , leukemia , physics , astrobiology
Summary No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22 + blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m 2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)‐positive patient became MRD‐negative. Six‐month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno‐occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.